SLX1B is active during transformation and controls relapse and resistance in human cancer.

We recently discovered SLX1B induction in a Brca1 deficient setting. To gain insight into processes SLX1B participates in, we quiered a collection of whole transcriptome datasets for SLX1B activation. A dataset describing transcriptional activity in TNBC cells in vitro comparing cells with response or no response to irinotecan was retrieved and used as a model for study of genomic instability in cancer cells. The data supported a hypothesis arguing that genomic instability, and changes in expression of any machinery that can generate such instability is a recurrent trigger that ultimately drives disease relapse in cancer (recurrence) and treatment failure during treatment for cancer (partial response or residual disease versus complete response).